ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA”), an end-to-end
commercial biopharmaceutical company dedicated to manufacturing,
marketing and developing specialty plasma-derived biologics, today
reported business highlights and financial results for its fiscal
second quarter and six months ended June 30, 2020, and provided an
overview of recent progress and accomplishments.
“The first half of 2020 was marked by several achievements and
challenges as we navigate through these unprecedented macro-market
conditions,” said Adam Grossman, President and Chief Executive
Officer of ADMA. “Total revenues for the first half of 2020
increased approximately 78% compared to the same prior year period.
While the second quarter 2020 revenues were approximately 19%
higher than second quarter 2019 revenues, ADMA, and certain of its
third-party vendors, experienced impacts from the global COVID-19
pandemic which resulted in unforeseen supply chain disruptions.
These COVID-19 disruptions were primarily related to delays with
final product Current Good Manufacturing Practice (“cGMP”) release
testing by third-party vendors. This means that a few of our
production batches were finished on schedule but we were unable to
submit for U.S. Food and Drug Administration (“FDA”) lot release
authorization due to delayed test results.
“These delays were mainly experienced during the latter part of
the second quarter and have since been resolved during July. In
response to these delays, and in partnership with the FDA, we added
additional release testing laboratories to our approved consortium
and believe we have completely resolved the issue and do not
anticipate additional testing or batch release delays going
forward.
“Market demand for our immunoglobulin product portfolio remains
strong and we anticipate considerable revenue growth for the second
half of the year and are excited for the anticipated production
volume increases from our capacity expansion efforts in 2021 and
beyond. We also believe we remain on track to achieve our stated
goal of generating $250 million or more in annual revenues within
the next three to five calendar years.
“In accordance with our stated corporate objectives, during the
quarter we completed construction of a new plasma collection
center, initiated donor collections and submitted a Biologics
License Application (“BLA”) to the FDA, with an approval decision
expected in mid-2021. We also installed and qualified a new aseptic
fill-finish machine at our Boca Raton facility, and manufactured
conformance batches of BIVIGAM® at an increased scale that will
ultimately allow us to manufacture at twice the volume as the
process that is in place today. And finally, we joined the CoVIg-19
Plasma Alliance and began collection of plasma from COVID-19
convalesced patients. We are proud of these important achievements
and milestones and believe we have set the stage to now be in a
position to ensure the U.S. market has a continuous supply of
BIVIGAM®, ASCENIV™ and NABI-HB®. We are on target for positioning
our operations to capitalize on the continued forecasted growth of
the plasma products industry. Our production throughput and
finished product supply remains on track to begin realizing the
benefits from these initiatives as early as mid-2021,” concluded
Mr. Grossman.
Second Quarter 2020 Highlights and Recent
Events
- Plasma Collection Centers – ADMA BioCenters, a
wholly-owned subsidiary of ADMA Biologics, successfully opened,
began donor collections and filed a BLA to receive FDA approval for
its second plasma collection center. ADMA expects to open a
third U.S. collection center and commence construction on a fourth
center by the end of 2020 and remains on track to deliver on its
stated milestone of opening five to ten new plasma collection
centers over the next three to five years.
- Plasma Industry Alliance – ADMA recently
joined the CoVIg-19 Plasma Alliance, an unprecedented plasma
industry collaboration established to accelerate the development of
a plasma-derived hyperimmune globulin therapy for COVID-19.
As an Alliance member company, ADMA, through its ADMA BioCenters
subsidiary, has initiated collecting and providing COVID-19 plasma
from convalesced patients. This plasma will be used by the
CoVIg-19 Plasma Alliance to produce a COVID-19 targeted hyperimmune
globulin, as well as for internal research and development
purposes.
- Manufacturing Capacity Expansion Initiatives –
ADMA successfully implemented several manufacturing and supply
chain enhancements, including the purchase and installation of a
new Vanrx SA25 Workcell aseptic filling machine and manufacturing
of four conformance batches of BIVIGAM® at an increased
scale. These important initiatives are designed to reduce
operating costs, improve margins and provide for faster production
cycle turnaround time, ultimately providing increased control and
independence from third-party vendors and contractors. ADMA
plans to submit the appropriate applications to the FDA during the
second half of 2020, and expects to begin benefitting from these
initiatives as early as mid-2021.
COVID-19 Impacts
- Final Product Release Testing – ADMA
experienced delays with final product release testing for its
commercial products due to COVID-19’s impact on third-party
laboratories that perform the FDA-required cGMP release
testing. These testing delays prevented ADMA from receiving
FDA authorization to sell additional completed production batches
during the second quarter. ADMA believes this delay was
completely resolved in July 2020. In response to these
delays, and in collaboration with the FDA, ADMA secured additional
third-party laboratories, which has completely resolved this
specific testing backlog. ADMA received FDA authorized
product releases with data from its new third-party testing
laboratories during July. Going forward, ADMA believes access to
these additional laboratories will provide more rapid final product
release testing as well as more consistent receipt of testing
results to submit to the FDA for final product releases.
- Supply Chain Impacts Due to COVID-19 – As a
result of previous state and local “shelter-in-place” orders, ADMA
experienced lower than normal donor collections at its FDA-licensed
plasma collection center during the second quarter of 2020.
ADMA also experienced delayed timing of shipments of source plasma
from its contracted third-party suppliers, as well as delays in
deliveries of personal protective equipment, reagents and other
non-plasma raw materials and supplies used in the manufacture of
its products.
- Commercial Engagement Opportunities – ADMA
observed impacts to its customer engagement initiatives as its
sales and medical affairs field forces experienced difficulty
communicating directly with physicians and other healthcare
professionals. In addition, a number of key scientific and
medical meetings were either canceled or postponed, further
limiting ADMA’s ability to communicate with potential
customers. ADMA has implemented a comprehensive suite of
virtual engagement initiatives; however, clinician engagement has
been reduced due to rapidly evolving COVID-19 priorities at U.S.
medical centers.
Financial Results for the Three Months Ended June 30,
2020
Total revenues for the quarter ended June 30, 2020 were $7.8
million, compared to $6.6 million for the quarter ended June 30,
2019, representing an increase of approximately $1.2 million, or
approximately 19%. The increase is primarily due to sales of
BIVIGAM, ASCENIV and intermediates, compared to no sales from these
products during the same prior year period. ADMA’s revenues
for the second quarter of 2020, compared to the second quarter of
2019, were favorably impacted by the FDA approvals of BIVIGAM and
ASCENIV on May 9, 2019 and April 1, 2019, respectively, and by the
manufacturing and supply agreement ADMA entered into in January
2020 to produce and sell intermediate fractions to a certain
customer.
Consolidated net loss for the quarter ended June 30, 2020 was
$20.2 million, or $(0.23) per basic and diluted share, compared to
a consolidated net loss of $13.2 million, or $(0.25) per basic and
diluted share, for the quarter ended June 30, 2019. The
increase in net loss of $7.0 million was primarily due to increased
cost of product revenue of $3.0 million related to sales of
FDA-approved immunoglobulin products not present in the same prior
year period, along with the remaining costs associated with the
manufacturing of BIVIGAM’s increased plasma pool conformance lots
as part of our planned capacity expansion, partially offset by a
decrease in unabsorbed manufacturing expense at the Boca Raton, FL
production facility. The increase in net loss during the
second quarter of 2020 is also attributable to higher research and
development expenses of $1.1 million, largely due to costs
associated with the testing and development of a new filling line
at one of our third-party fill finishers, and to increased selling,
general and administrative expenses of $2.6 million, mainly due to
increases in employee compensation expenses and other costs in
support of our commercialization efforts for BIVIGAM and ASCENIV.
In addition, interest expense for the quarter increased by $1.0
million due to our accessing additional debt during the second
quarter of 2019 and first quarter of 2020. Included in the
net loss for the second quarter of 2020 were non-cash expenses of
approximately $2.0 million for stock-based compensation,
depreciation and amortization, and non-cash interest expense.
Financial Results for the Six Months Ended June 30,
2020
Total revenues for the six months ended June 30, 2020 were $18.0
million, compared to $10.1 million for the six months ended June
30, 2019, representing an increase of $7.9 million, or
approximately 78%. The increase in revenues was primarily
attributable to sales of BIVIGAM, ASCENIV and intermediates,
compared to no sales from these products during the same prior year
period.
Consolidated net loss for the six months ended June 30, 2020 was
$39.4 million, or $(0.49) per basic and diluted share, compared to
a consolidated net loss of $26.3 million, or $(0.53) per basic and
diluted share, for the six months ended June 30, 2019. The
increase in net loss of $13.1 million was primarily attributable to
increased cost of product revenue of $10.4 million related to sales
of BIVIGAM, ASCENIV and intermediates not present during the first
half of 2019, along with the costs associated with the
manufacturing of BIVIGAM’s increased plasma pool conformance lots
as part of our planned capacity expansion, along with other
production initiatives and investments at the Boca Raton
facility. Other factors contributing to the increase in net
loss include: higher research and development expenses attributed
to costs associated with testing and development of a new fill line
at our third-party fill finisher and costs incurred for a study we
commenced to potentially extend ASCENIV’s approved and labeled
expiration dating, higher selling, general administrative expenses
in support of our commercialization efforts of BIVIGAM’s relaunch
and ASCENIV’s launch and the overall growth in the size and scope
of the Company’s operations along with higher interest expense due
to accessing additional debt during the second quarter of 2019 and
first quarter of 2020. Included in the net loss for the first
half of 2020 were non-cash expenses of approximately $3.9 million
for stock-based compensation, depreciation and amortization, and
non-cash interest expense.
At June 30, 2020, ADMA had cash and cash equivalents of $75.8
million and accounts receivable of $6.5 million, compared to cash
and cash equivalents of $26.8 million and accounts receivable of
$3.5 million at December 31, 2019. ADMA’s net working capital
as of June 30, 2020 was $130.1 million, compared to $71.8 million
as of December 31, 2019.
Conference Call Information
ADMA will host a conference call today, Wednesday, August 5,
2020, at 4:30 p.m. Eastern Time, to discuss the second quarter 2020
financial results and recent corporate updates. To access the
conference call, please dial (855) 884-8773 (local) or (615)
622-8043 (international) at least 10 minutes prior to the start
time and refer to conference ID 8992308. A live audio webcast
of the call will be available under "Events & Webcasts" in the
Investor section of the Company's website,
https://ir.admabiologics.com/events-webcasts. An archived
webcast will be available on the Company's website approximately
two hours after the event.
About BIVIGAM®
BIVIGAM (immune globulin intravenous, human – 10% liquid) is a
plasma-derived, polyclonal, intravenous immune globulin
(IVIG). BIVIGAM was approved by the FDA in May 2019 and is
indicated for the treatment of primary humoral immunodeficiency
(PI), including, but not limited to the following group of genetic
disorders: X-linked and congenital agammaglobulinemia, common
variable immunodeficiency, Wiskott-Aldrich syndrome and severe
combined immunodeficiency. BIVIGAM contains a broad range of
antibodies similar to those found in normal human plasma.
These antibodies are directed against bacteria and viruses and help
to protect PI patients against serious infections. BIVIGAM is
a purified, sterile, ready-to-use preparation of concentrated human
Immunoglobulin (IgG) antibodies.
About ASCENIV™
ASCENIV (immune globulin intravenous, human – slra 10% liquid)
is a plasma-derived, polyclonal, intravenous immune globulin
(IVIG). ASCENIV was approved by the FDA on April 1,
2019 and is indicated for the treatment of primary humoral
immunodeficiency (PI), also known as primary immune deficiency
disease (PIDD), in adults and adolescents (12 to 17 years of
age). ASCENIV is manufactured using ADMA’s unique, patented
plasma donor screening methodology and tailored plasma pooling
design, which blends normal source plasma and plasma from donors
tested using the Company’s proprietary microneutralization
assay. ASCENIV contains naturally occurring polyclonal
antibodies, which are proteins that are used by the body’s immune
system to neutralize microbes, such as bacteria and viruses and
prevent against infection and disease. ASCENIV is protected
by U.S. Patents: 9,107,906, 9,714,283 and 9,815,886.
About Nabi-HB®
Nabi-HB® is a hyperimmune globulin that is rich in antibodies to
the Hepatitis B virus. Nabi-HB® is a purified human polyclonal
antibody product collected from plasma donors who have been
previously vaccinated with a Hepatitis B vaccine. Nabi-HB® is
indicated for the treatment of acute exposure to blood containing
Hepatitis B surface antigen (“HBsAg”), prenatal exposure to infants
born to HBsAg-positive mothers, sexual exposure to HBsAg-positive
persons and household exposure to persons with acute Hepatitis B
virus infection. Hepatitis B is a potentially life-threatening
liver infection caused by the Hepatitis B virus. It is a major
global health problem and can cause chronic infection and put
people at high risk of death from cirrhosis and liver cancer.
Nabi-HB® has a well-documented record of long-term safety and
effectiveness since its initial market introduction. Certain data
and other information about Nabi-HB® or ADMA Biologics and its
products can be found on the Company’s website at
www.admabiologics.com.
About ADMA BioCenters
ADMA BioCenters is an FDA licensed facility specializing in the
collection of human plasma used to make special medications for the
treatment and prevention of diseases. Managed by a team of experts
who have decades of experience in the specialized field of plasma
collection, ADMA BioCenters provides a safe, professional and
pleasant donation environment. ADMA BioCenters strictly follows FDA
regulations and guidance and enforces cGMP (current good
manufacturing practices) in all of its facilities. For more
information about ADMA BioCenters, please visit
www.atlantaplasma.com.
About ADMA Biologics, Inc. (ADMA)
ADMA Biologics is an end-to-end commercial biopharmaceutical
company dedicated to manufacturing, marketing and developing
specialty plasma-derived biologics for the treatment of
immunodeficient patients at risk for infection and others at risk
for certain infectious diseases. ADMA currently manufactures
and markets three United States Food and Drug Administration (FDA)
approved plasma-derived biologics for the treatment of immune
deficiencies and the prevention of certain infectious diseases:
ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for
the treatment of primary humoral immunodeficiency (PI); BIVIGAM®
(immune globulin intravenous, human) for the treatment of PI; and
NABI-HB® (hepatitis B immune globulin, human) to provide enhanced
immunity against the hepatitis B virus. ADMA manufactures its
immune globulin products at its FDA-licensed plasma fractionation
and purification facility located in Boca Raton, Florida. Through
its ADMA Bio Centers subsidiary, ADMA also operates as an
FDA-approved source plasma collector in the U.S., which provides a
portion of its blood plasma for the manufacture of its products.
ADMA’s mission is to manufacture, market and develop specialty
plasma-derived, human immune globulins targeted to niche patient
populations for the treatment and prevention of certain infectious
diseases and management of immune compromised patient populations
who suffer from an underlying immune deficiency, or who may be
immune compromised for other medical reasons. ADMA has received
U.S. Patents: 9,107,906, 9,714,283, 9,815,886, 9,969,793 and
10,259,865 related to certain aspects of its products and product
candidates. For more information, please visit
www.admabiologics.com.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains “forward-looking statements”
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995, about ADMA Biologics, Inc. (“we,”
“our” or the “Company”). Forward-looking statements include,
without limitation, any statement that may predict, forecast,
indicate, or imply future results, performance or achievements, and
may contain such words as “estimate,” “project,” “intend,”
“forecast,” “target,” “anticipate,” “plan,” “planning,” “expect,”
“believe,” “will,” “should,” “could,” “would,” “may,” or, in each
case, their negative, or words or expressions of similar meaning.
These forward-looking statements also include, but are not limited
to, statements about ADMA’s future results of operations, including
the goal of generating $250 million or more in annual revenues
within the next three to five calendar years; our belief that we
have corrected third-party release testing delay issues through the
addition of release testing laboratories to our FDA-approved
consortium; the outcome and timing of our BLA application for our
new plasma center; the expected benefits from the new aseptic
fill-finish machine installed at our Boca Raton facility; the
continued forecasted growth of the plasma products industry and our
expectation to capitalize thereon; the construction and opening of
plasma collection centers and the timing thereof; the expected and
intended use by the CoVIg-19 Plasma Alliance of plasma that we
collect; the benefits expected from our several manufacturing and
supply chain enhancement, the expected timing for realizing those
benefits, and our plan to submit appropriate applications to the
FDA related thereto; and the expected benefits from securing
additional third-party laboratories to perform cGMP release
testing. Actual events or results may differ materially from those
described in this document due to a number of important factors.
Current and prospective security holders are cautioned that there
also can be no assurance that the forward-looking statements
included in this press release will prove to be accurate. Except to
the extent required by applicable laws or rules, ADMA does not
undertake any obligation to update any forward-looking statements
or to announce revisions to any of the forward-looking statements.
Forward-looking statements are subject to many risks, uncertainties
and other factors that could cause our actual results, and the
timing of certain events, to differ materially from any future
results expressed or implied by the forward-looking statements,
including, but not limited to, the risks and uncertainties
described in our filings with the U.S. Securities and Exchange
Commission, including our most recent reports on Form 10-K, 10-Q
and 8-K, and any amendments thereto.
COMPANY CONTACT:
Brian Lenz
Executive Vice President and Chief Financial Officer |
201-478-5552 |www.admabiologics.com
INVESTOR RELATIONS CONTACT:
Sam Martin
Managing Director, Argot Partners | 212-600-1902 |
sam@argotpartners.com
ADMA BIOLOGICS, INC. AND
SUBSIDIARIESCONSOLIDATED STATEMENTS OF
OPERATIONS
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
|
2020 |
|
2019 |
|
2020 |
|
2019 |
|
|
|
|
|
|
|
|
REVENUES: |
|
|
|
|
|
|
|
Product revenue |
$ |
7,751,885 |
|
|
$ |
6,525,233 |
|
|
$ |
17,915,921 |
|
|
$ |
10,018,114 |
|
License revenue |
|
35,709 |
|
|
|
35,709 |
|
|
|
71,417 |
|
|
|
71,417 |
|
Total Revenues |
|
7,787,594 |
|
|
|
6,560,942 |
|
|
|
17,987,338 |
|
|
|
10,089,531 |
|
|
|
|
|
|
|
|
|
OPERATING
EXPENSES: |
|
|
|
|
|
|
|
Cost of product revenue (exclusive of amortization expense shown
below) |
|
13,495,629 |
|
|
|
10,491,236 |
|
|
|
30,324,855 |
|
|
|
19,896,415 |
|
Research and development |
|
1,656,420 |
|
|
|
516,986 |
|
|
|
3,185,158 |
|
|
|
1,387,621 |
|
Plasma center operating expenses |
|
877,902 |
|
|
|
594,113 |
|
|
|
1,378,546 |
|
|
|
1,248,599 |
|
Amortization of intangible assets |
|
178,838 |
|
|
|
211,234 |
|
|
|
357,676 |
|
|
|
422,469 |
|
Selling, general and administrative |
|
8,702,630 |
|
|
|
6,086,047 |
|
|
|
16,634,714 |
|
|
|
11,681,517 |
|
Total operating expenses |
|
24,911,419 |
|
|
|
17,899,616 |
|
|
|
51,880,949 |
|
|
|
34,636,621 |
|
|
|
|
|
|
|
|
|
LOSS FROM
OPERATIONS |
|
(17,123,825 |
) |
|
|
(11,338,674 |
) |
|
|
(33,893,611 |
) |
|
|
(24,547,090 |
) |
|
|
|
|
|
|
|
|
OTHER INCOME
(EXPENSE): |
|
|
|
|
|
|
|
Interest and other income |
|
19,411 |
|
|
|
209,808 |
|
|
|
267,479 |
|
|
|
337,207 |
|
Interest expense |
|
(3,067,306 |
) |
|
|
(2,072,578 |
) |
|
|
(5,784,397 |
) |
|
|
(3,613,085 |
) |
Loss on extinguishment of debt |
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(9,962,495 |
) |
Gain on transfer of plasma center assets |
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
11,527,421 |
|
Other expense, net |
|
(6,371 |
) |
|
|
(10,428 |
) |
|
|
(12,792 |
) |
|
|
(21,785 |
) |
Other expense, net |
|
(3,054,266 |
) |
|
|
(1,873,198 |
) |
|
|
(5,529,710 |
) |
|
|
(1,732,737 |
) |
|
|
|
|
|
|
|
|
NET LOSS |
$ |
(20,178,091 |
) |
|
$ |
(13,211,872 |
) |
|
$ |
(39,423,321 |
) |
|
$ |
(26,279,827 |
) |
|
|
|
|
|
|
|
|
BASIC AND DILUTED LOSS
PER COMMON SHARE |
$ |
(0.23 |
) |
|
$ |
(0.25 |
) |
|
$ |
(0.49 |
) |
|
$ |
(0.53 |
) |
|
|
|
|
|
|
|
|
WEIGHTED AVERAGE
COMMON SHARES OUTSTANDING: |
|
|
|
|
|
|
|
Basic and Diluted |
|
86,347,467 |
|
|
|
52,206,204 |
|
|
|
80,064,641 |
|
|
|
49,295,805 |
|
|
ADMA BIOLOGICS, INC. AND
SUBSIDIARIESCONDENSED CONSOLIDATED BALANCE
SHEETS
|
|
|
|
|
June 30, |
|
December 31, |
|
2020 |
|
2019 |
ASSETS |
(Unaudited) |
|
|
Current assets: |
|
|
|
Cash and cash equivalents |
$ |
75,781,122 |
|
|
$ |
26,752,135 |
|
Accounts receivable, net |
|
6,514,165 |
|
|
|
3,469,919 |
|
Inventories |
|
56,001,348 |
|
|
|
53,064,734 |
|
Prepaid expenses and other current assets |
|
4,693,427 |
|
|
|
2,533,593 |
|
Total current assets |
|
142,990,062 |
|
|
|
85,820,381 |
|
Property and equipment,
net |
|
37,373,366 |
|
|
|
31,741,317 |
|
Intangible assets, net |
|
2,801,797 |
|
|
|
3,159,474 |
|
Goodwill |
|
3,529,509 |
|
|
|
3,529,509 |
|
Deposits and other assets |
|
4,846,834 |
|
|
|
2,840,044 |
|
TOTAL
ASSETS |
$ |
191,541,568 |
|
|
$ |
127,090,725 |
|
|
|
|
|
LIABILITIES AND
STOCKHOLDERS' EQUITY |
|
|
|
Current liabilities: |
|
|
|
Accounts payable |
$ |
6,909,659 |
|
|
$ |
9,174,591 |
|
Accrued expenses and other current liabilities |
|
5,616,666 |
|
|
|
4,481,395 |
|
Current portion of deferred revenue |
|
142,834 |
|
|
|
142,834 |
|
Current portion of lease obligations |
|
210,870 |
|
|
|
229,073 |
|
Total current liabilities |
|
12,880,029 |
|
|
|
14,027,893 |
|
Senior notes payable, net of
discount |
|
81,648,187 |
|
|
|
68,291,163 |
|
Deferred revenue, net of
current portion |
|
2,190,115 |
|
|
|
2,261,532 |
|
Subordinated note payable, net
of discount |
|
14,925,760 |
|
|
|
14,908,053 |
|
Lease obligations, net of
current portion |
|
2,937,292 |
|
|
|
1,302,361 |
|
Other non-current
liabilities |
|
80,730 |
|
|
|
106,574 |
|
TOTAL
LIABILITIES |
|
114,662,113 |
|
|
|
100,897,576 |
|
|
|
|
|
COMMITMENTS AND
CONTINGENCIES |
|
|
|
|
|
|
|
STOCKHOLDERS'
EQUITY |
|
|
|
Preferred Stock, $0.0001 par
value, 10,000,000 shares authorized, no shares issued and
outstanding |
|
- |
|
|
|
- |
|
Common Stock, $0.0001 par
value, 150,000,000 shares authorized, 86,349,981 and 59,318,355
shares issued and outstanding |
|
8,635 |
|
|
|
5,932 |
|
Additional paid-in
capital |
|
381,010,696 |
|
|
|
290,903,772 |
|
Accumulated deficit |
|
(304,139,876 |
) |
|
|
(264,716,555 |
) |
TOTAL STOCKHOLDERS'
EQUITY |
|
76,879,455 |
|
|
|
26,193,149 |
|
TOTAL LIABILITIES AND
STOCKHOLDERS' EQUITY |
$ |
191,541,568 |
|
|
$ |
127,090,725 |
|
Adma Biologics (NASDAQ:ADMA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adma Biologics (NASDAQ:ADMA)
Historical Stock Chart
From Apr 2023 to Apr 2024